Results 91 to 100 of about 96,616 (241)

Impact of highly active immunotherapy on acute and chronic neuroinflammation in aggressive multiple sclerosis

open access: yes, 2023
Background: Despite the use of new high efficacy therapies, complete disease remission is elusive in most people with multiple sclerosis (MS). This is particularly relevant for patients affected by aggressive MS, who deal with frequent relapses and accelerated accrual of irreversible disability.
openaire   +1 more source

Engagement Patterns With an Artificial Intelligence Health Coach for Systemic Sclerosis Self‐Management: A Mixed Methods Study

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate utility of an artificial intelligence (AI) health coach for systemic sclerosis (SSc) self‐management and identify patterns associated with participant engagement. Methods We conducted a mixed methods study in which an AI health coach, powered by a large language model (LLM), was used to support self‐management for SSc.
Nirali Shah   +4 more
wiley   +1 more source

Hemianopia and visual loss due to progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis

open access: yesClinical Ophthalmology, 2012
Tina Rike Herold,1 Veronika Jakl,3 Anno Graser,4 Kirsten Eibl-Lindner1,21Department of Ophthalmology, 2Department of Ophthalmology, Campus Innenstadt, 3Department of Neurology, 4Department of Clinical Radiology, Campus Grosshadern, University of Munich ...
Herold TR   +3 more
doaj  

Impact of Six‐Month Monitoring Compared to Three‐Month Monitoring of Laboratories During Methotrexate Therapy

open access: yesArthritis Care &Research, EarlyView.
Objective To evaluate whether extending the American College of Rheumatology–recommended monitoring interval for complete blood count and liver function tests in patients receiving methotrexate (MTX) affects timely detection of medication‐related toxicity.
Spencer Simko   +4 more
wiley   +1 more source

Beyond Visual Scoring: Computational CT‐analysis for HRCT based quantification of Interstitial Lung Disease in Inflammatory Rheumatic Disease

open access: yesArthritis Care &Research, Accepted Article.
Interstitial lung disease (IRD‐ILD) is a significant cause of morbidity and mortality in patients with inflammatory rheumatic disorders (IRD). High‐resolution computed tomography (HRCT) is widely considered the gold standard for the non‐invasive assessment of ILD; however, its interpretation is constrained by substantial inter‐observer variability and ...
Alexander Pfeil   +7 more
wiley   +1 more source

Facial cosmetic therapy use amongst patients with systemic sclerosis: an Australian cohort study

open access: yesArthritis Care &Research, Accepted Article.
Objective Systemic sclerosis (SSc) is associated with numerous facial manifestations for which patients may engage in cosmetic therapies. It is unclear how patients with SSc use these therapies. This study sought to characterise patient engagement and experiences with cosmetic therapies for SSc‐related and non‐SSc‐related facial changes.
Zachary Warren   +11 more
wiley   +1 more source

Ionizable Lipid‐Dependent Optimization of Steroid Lipid Nanoparticles With Tunable Immunomodulatory Properties

open access: yesAdvanced Materials, EarlyView.
A novel engineering strategy that establishes material design principles for incorporating anti‐inflammatory steroids into lipid nanoparticles to reduce LNP‐induced inflammation while retaining mRNA delivery. Results are validated in vitro and in three animal models of inflammation and autoimmunity in vivo.
Ajay S. Thatte   +21 more
wiley   +1 more source

Elastomeric 3D‐Printed Microenvironments Enable Nanonewton Force Measurements in Healthy and Diseased Human Pluripotent Stem Cell‐Derived Neuroepithelial Cells

open access: yesAdvanced Materials, EarlyView.
We present elastomeric three‐dimensional (3D) microstructures fabricated via two‐photon polymerization (2PP) and post‐processed through wet etching, for quantifying nanonewton (nN)‐scale forces applied by healthy and diseased neural cells. The mechanically characterized free‐standing beam architectures enable measurement of traction forces of ...
Pieter F. J. van Altena   +7 more
wiley   +1 more source

Alemtuzumab for the treatment of multiple sclerosis

open access: yesTherapeutics and Clinical Risk Management, 2015
Mark D Willis, Neil P Robertson Institute of Psychological Medicine and Clinical Neuroscience, Cardiff University, University Hospital of Wales, Heath Park, Cardiff, UK Abstract: Alemtuzumab is an anti-CD52 monoclonal antibody, recently approved for ...
Willis MD, Robertson NP
doaj  

Home - About - Disclaimer - Privacy